Zontivity Approval Status
- FDA approved: No
- Brand name: Zontivity
- Generic name: vorapaxar
- Company: Merck
- Treatment for: Cardiovascular Risk Reduction
Zontivity (vorapaxar) is an investigational anti-thrombotic medicine in development for the secondary prevention of cardiovascular events.
FDA Approval Status for Zontivity
|Jan 15, 2014||Merck Statement on FDA Advisory Committee for Vorapaxar, Merck’s Investigational Antiplatelet Medicine|
|Jul 24, 2013||Merck Announces FDA Acceptance of New Drug Application for Vorapaxar, Investigational Anti-Thrombotic Medicine|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.